Declan G Murphy

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/5984662/declan-g-murphy-publications-by-year.pdf

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

185 6,607 40 78 g-index

229 8,759 5.9 6.02 ext. papers ext. citations avg, IF L-index

#	Paper	IF	Citations
185	How Does Age Affect Urinary Continence following Robot-Assisted Radical Prostatectomy? A Prospective Multi-Institutional Study Using Independently Collected, Validated Questionnaires <i>Journal of Urology</i> , 2022 , 101097JU000000000002391	2.5	0
184	Robotic partial nephrectomy for hilar renal masses. <i>Urology Video Journal</i> , 2022 , 13, 100117	0.2	
183	Re: Armando Stabile, Antony Pellegrino, Elio Mazzone, et al. Can Negative Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Avoid the Need for Pelvic Lymph Node Dissection in Newly Diagnosed Prostate Cancer Patients? A Systematic Review	6.7	
182	Re: Darolutamide and Survival in Metastatic, Hormone-sensitive Prostate Cancer <i>European Urology</i> , 2022 ,	10.2	
181	Accuracy Versus Impact: The Referee Verdict on Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography for Staging of Prostate Cancer. <i>European Urology Open Science</i> , 2021 , 34, 83-85	0.9	
180	Predictors of real-world utilisation of docetaxel combined with androgen deprivation therapy in metastatic hormone-sensitive prostate cancer. <i>Internal Medicine Journal</i> , 2021 ,	1.6	3
179	Positron Emission Tomography and Whole-body Magnetic Resonance Imaging for Metastasis-directed Therapy in Hormone-sensitive Oligometastatic Prostate Cancer After Primary Radical Treatment: A Systematic Review. <i>European Urology Oncology</i> , 2021 , 4, 714-730	6.7	3
178	Patterns of primary staging for newly diagnosed prostate cancer in the era of prostate specific membrane antigen positron emission tomography: A population-based analysis. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2021 , 65, 649-654	1.7	0
177	UpFrontPSMA: a randomized phase 2 study of sequential Lu-PSMA-617 and docetaxel vs docetaxel in metastatic hormone-nalle prostate cancer (clinical trial protocol). <i>BJU International</i> , 2021 , 128, 331-3	4 5 .6	13
176	Ductal variant prostate carcinoma is associated with a significantly shorter metastasis-free survival. European Journal of Cancer, 2021 , 148, 440-450	7.5	3
175	Oncological outcomes of salvage radical prostatectomy for recurrent prostate cancer in the contemporary era: A multicenter retrospective study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021 , 39, 296.e21-296.e29	2.8	6
174	Ga-PSMA-PET screening and transponder-guided salvage radiotherapy to the prostate bed alone for biochemical recurrence following prostatectomy: interim outcomes of a phase II trial. <i>World Journal of Urology</i> , 2021 , 39, 4117-4125	4	
173	Role of PSMA PET/CT imaging in the diagnosis, staging and restaging of prostate cancer. <i>Future Oncology</i> , 2021 , 17, 2225-2241	3.6	3
172	Clinical Trial Protocol for LuTectomy: A Single-arm Study of the Dosimetry, Safety, and Potential Benefit of Lu-PSMA-617 Prior to Prostatectomy. <i>European Urology Focus</i> , 2021 , 7, 234-237	5.1	13
171	Re: Enzalutamide and Survival in Non-metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2021 , 79, 320-321	10.2	
170	Re: Olaparib for Metastatic Castration-resistant Prostate Cancer. European Urology, 2021 , 79, 319-320	10.2	_
169	Management of patients who opt for radical prostatectomy during the coronavirus disease 2019 (COVID-19) pandemic: an international accelerated consensus statement. <i>BJU International</i> , 2021 , 127, 729-741	5.6	5

(2020-2021)

168	Is Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Imaging Cost-effective in Prostate Cancer: An Analysis Informed by the proPSMA Trial. <i>European Urology</i> , 2021 , 79, 413-418	10.2	15
167	The effect of exercise training on cardiometabolic health in men with prostate cancer receiving androgen deprivation therapy: a systematic review and meta-analysis. <i>Prostate Cancer and Prostatic Diseases</i> , 2021 , 24, 35-48	6.2	6
166	Current treatment options for newly diagnosed metastatic hormone-sensitive prostate cancer-a narrative review. <i>Translational Andrology and Urology</i> , 2021 , 10, 3918-3930	2.3	1
165	The MURAL collection of prostate cancer patient-derived xenografts enables discovery through preclinical models of uro-oncology. <i>Nature Communications</i> , 2021 , 12, 5049	17.4	6
164	The Additive Diagnostic Value of Prostate-specific Membrane Antigen Positron Emission Tomography Computed Tomography to Multiparametric Magnetic Resonance Imaging Triage in the Diagnosis of Prostate Cancer (PRIMARY): A Prospective Multicentre Study. <i>European Urology</i> , 2021 ,	10.2	21
163	80, 682-689 The application of theranostics in different stages of prostate cancer. Future Oncology, 2021 , 17, 3637-	3 6 464	O
162	Navigate: a study protocol for a randomised controlled trial of an online treatment decision aid for men with low-risk prostate cancer and their partners. <i>Trials</i> , 2021 , 22, 49	2.8	О
161	Ductal adenocarcinoma of the prostate: A systematic review and meta-analysis of incidence, presentation, prognosis, and management <i>BJUI Compass</i> , 2021 , 2, 13-23	0.9	2
160	Prostate-specific membrane antigen theranostics in advanced prostate cancer: an evolving option. <i>BJU International</i> , 2020 , 126, 525-535	5.6	8
159	Knowing whath growing: Why ductal and intraductal prostate cancer matter. <i>Science Translational Medicine</i> , 2020 , 12,	17.5	13
158	Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. <i>Lancet, The</i> , 2020 , 395, 1208-1216	40	472
157	Prognostic biomarkers in men with metastatic castration-resistant prostate cancer receiving [177Lu]-PSMA-617. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020 , 47, 2322-2327	8.8	51
156	Use of prostate-specific membrane antigen positron-emission tomography/CT in response assessment following upfront chemohormonal therapy in metastatic prostate cancer. <i>BJU International</i> , 2020 , 126, 433-435	5.6	3
155	"TREXIT 2020": why the time to abandon transrectal prostate biopsy starts now. <i>Prostate Cancer and Prostatic Diseases</i> , 2020 , 23, 62-65	6.2	32
154	Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. <i>European Urology</i> , 2020 , 77, 508-547	10.2	155
153	Protocol for the PRIMARY clinical trial, a prospective, multicentre, cross-sectional study of the additive diagnostic value of gallium-68 prostate-specific membrane antigen positron-emission tomography/computed tomography to multiparametric magnetic resonance imaging in the	5.6	29
152	Complications and 5-year survival after radical resections which include urological organs for locally advanced and recurrent pelvic malignancies: analysis of 646 consecutive cases. <i>Techniques in Coloproctology</i> , 2020 , 24, 181-190	2.9	2
151	Expanding the role of small-molecule PSMA ligands beyond PET staging of prostate cancer. <i>Nature Reviews Urology</i> , 2020 , 17, 107-118	5.5	18

150	Social Media Coverage of Scientific Articles Immediately After Publication Predicts Subsequent Citations - #SoME_Impact Score: Observational Analysis. <i>Journal of Medical Internet Research</i> , 2020 , 22, e12288	7.6	10
149	Testing Consultation Recordings in a Clinical Setting With the SecondEars Smartphone App: Mixed Methods Implementation Study. <i>JMIR MHealth and UHealth</i> , 2020 , 8, e15593	5.5	6
148	Cerenkov Luminescence Imaging for Surgical Margins in Radical Prostatectomy: A Surgical Perspective. <i>Journal of Nuclear Medicine</i> , 2020 , 61, 1498-1499	8.9	1
147	Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in the Detection of Clinically Significant Prostate Cancer in the Prostate Imaging Reporting and Data System Era: A Systematic Review and Meta-analysis. <i>European Urology</i> , 2020 , 78, 402-414	10.2	65
146	Re: A Comparative Study of Robot-assisted and Open Radical Prostatectomy in 10 790 Men Treated by Highly Trained Surgeons for Both Procedures. <i>European Urology</i> , 2020 , 77, 285-286	10.2	
145	Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of Lu-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2020 , 61, 857-865	8.9	99
144	Novel agents for metastatic hormone-sensitive prostate cancer - a practice guide for urologists. <i>BJU International</i> , 2020 , 125, 342-345	5.6	5
143	Indirect Comparisons of Efficacy between Combination Approaches in Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Network Meta-analysis. <i>European Urology</i> , 2020 , 77, 365-372	10.2	56
142	Early Online Attention Can Predict Citation Counts for Urological Publications: The #UroSoMe_Score. <i>European Urology Focus</i> , 2020 , 6, 458-462	5.1	7
141	Re: F-Fluciclovine PET-CT and Ga-PSMA-11 PET-CT in Patients with Early Biochemical Recurrence After Prostatectomy: A Prospective, Single-centre, Single-arm, Comparative Imaging Trial. <i>European Urology</i> , 2020 , 77, 392-393	10.2	1
140	Chemotherapy, not androgen receptor-targeted therapy should be used upfront for metastatic hormone-sensitive prostate cancer. CON: Novel oral agents provide an attractive alternative to chemotherapy in metastatic hormone-sensitive prostate cancer. <i>Current Opinion in Urology</i> , 2020 ,	2.8	0
139	30, 620-622 Understanding the diagnosis of prostate cancer. <i>Medical Journal of Australia</i> , 2020 , 213, 424-429	4	2
138	Robotic multivisceral pelvic resection: experience from an exenteration unit. <i>Techniques in Coloproctology</i> , 2020 , 24, 1145-1153	2.9	3
137	Review of the use of prophylactic drain tubes post-robotic radical prostatectomy: Dogma or decent practice?. <i>BJUI Compass</i> , 2020 , 1, 122-125	0.9	O
136	PET imaging in urology: a rapidly growing successful collaboration. <i>Current Opinion in Urology</i> , 2020 , 30, 623-627	2.8	1
135	Robotic prostatectomy after abandoned open radical prostatectomy-Technical aspects and outcomes <i>BJUI Compass</i> , 2020 , 1, 174-179	0.9	
134	Subinguinal orchiectomy-A minimally invasive approach to open surgery <i>BJUI Compass</i> , 2020 , 1, 160-1	64 .9	
133	Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer-Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis.	10.2	344

(2019-2020)

132	Detection and localisation of primary prostate cancer using gallium prostate-specific membrane antigen positron emission tomography/computed tomography compared with multiparametric magnetic resonance imaging and radical prostatectomy specimen pathology. <i>BJU International</i> ,	5.6	31
131	Re: PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients with Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2020 , 77, 130-131	10.2	2
130	Poor Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer with Low Prostate-specific Membrane Antigen (PSMA) Expression Deemed Ineligible for Lu-labelled PSMA Radioligand Therapy. <i>European Urology Oncology</i> , 2019 , 2, 670-676	6.7	74
129	Going nuclear: it is time to embed the nuclear medicine physician in the prostate cancer multidisciplinary team. <i>BJU International</i> , 2019 , 124, 551	5.6	11
128	Establishing a cryopreservation protocol for patient-derived xenografts of prostate cancer. <i>Prostate</i> , 2019 , 79, 1326-1337	4.2	10
127	Re: Darolutamide in Nonmetastatic Castration-Resistant Prostate Cancer. <i>European Urology</i> , 2019 , 76, 536-537	10.2	1
126	Re: Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. <i>European Urology</i> , 2019 , 76, 126-127	10.2	3
125	Adding Colour to the Grey Zone of Advanced Prostate Cancer. European Urology Focus, 2019, 5, 123-124	1 5.1	3
124	Strategies for Evaluation of Novel Imaging in Prostate Cancer: Putting the Horse Back Before the Cart. <i>Journal of Clinical Oncology</i> , 2019 , 37, 765-769	2.2	24
123	The influence of BRCA2 mutation on localized prostate cancer. <i>Nature Reviews Urology</i> , 2019 , 16, 281-2	99 5	36
122	Report of the third Asian Prostate Cancer study meeting. Prostate International, 2019, 7, 60-67	3.4	4
121	Current management of radiation cystitis: a review and practical guide to clinical management. <i>BJU International</i> , 2019 , 123, 585-594	5.6	28
120	Management of patients with advanced prostate cancer in the Asia Pacific region: Neal-worldN consideration of results from the Advanced Prostate Cancer Consensus Conference (APCCC) 2017. BJU International, 2019, 123, 22-34	5.6	20
119	Re: Enzalutamide with Standard First-line Therapy in Metastatic Prostate Cancer. <i>European Urology</i> , 2019 , 76, 872-873	10.2	1
118	A Cost-effectiveness Analysis of Systemic Therapy for Metastatic Hormone-sensitive Prostate Cancer. <i>European Urology Oncology</i> , 2019 , 2, 649-655	6.7	33
117	The role of prostate-specific membrane antigen PET/computed tomography in primary staging of prostate cancer. <i>Current Opinion in Urology</i> , 2019 , 29, 569-577	2.8	10
116	PSMA PET applications in the prostate cancer journey: from diagnosis to theranostics. <i>World Journal of Urology</i> , 2019 , 37, 1255-1261	4	24
115	Voxel-wise correlation of positron emission tomography/computed tomography with multiparametric magnetic resonance imaging and histology of the prostate using a sophisticated registration framework. BUI International 2019, 123, 1020-1030.	5.6	7

114	Dosimetry of Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes. <i>Journal of Nuclear Medicine</i> , 2019 , 60, 517-523	8.9	144
113	Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition. <i>British Journal of Cancer</i> , 2018 , 118, 266-276	8.7	9
112	Voxel-wise prostate cell density prediction using multiparametric magnetic resonance imaging and machine learning. <i>Acta Oncològica</i> , 2018 , 57, 1540-1546	3.2	10
111	Laparoscopic and robot-assisted vs open radical prostatectomy for the treatment of localized prostate cancer: a Cochrane systematic review. <i>BJU International</i> , 2018 , 121, 845-853	5.6	54
110	Cold Kit for Prostate-Specific Membrane Antigen (PSMA) PET Imaging: Phase 1 Study of Ga-Tris(Hydroxypyridinone)-PSMA PET/CT in Patients with Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2018 , 59, 625-631	8.9	50
109	Intraductal carcinoma of the prostate can evade androgen deprivation, with emergence of castrate-tolerant cells. <i>BJU International</i> , 2018 , 121, 971-978	5.6	27
108	STAMPEDE-ing towards androgen biosynthesis inhibition for treatment of high-risk hormone-nalle prostate cancer: changing the LATITUDE. <i>BJU International</i> , 2018 , 121, 9-11	5.6	2
107	Changing face of robot-assisted radical prostatectomy in Melbourne over 12 years. <i>ANZ Journal of Surgery</i> , 2018 , 88, E200-E203	1	6
106	Patient-derived Models of Abiraterone- and Enzalutamide-resistant Prostate Cancer Reveal Sensitivity to Ribosome-directed Therapy. <i>European Urology</i> , 2018 , 74, 562-572	10.2	51
105	Active surveillance of men with low risk prostate cancer: evidence from the Prostate Cancer Outcomes Registry-Victoria. <i>Medical Journal of Australia</i> , 2018 , 208, 439-443	4	13
104	[Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. <i>Lancet Oncology, The</i> , 2018 , 19, 825-83	3 ^{21.7}	545
103	A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol. <i>BJU International</i> ,	5.6	67
102	Advances in Urologic Imaging: Prostate-Specific Membrane Antigen Ligand PET Imaging. <i>Urologic Clinics of North America</i> , 2018 , 45, 503-524	2.9	19
101	PRECISION delivers on the PROMIS of mpMRI in early detection. <i>Nature Reviews Urology</i> , 2018 , 15, 529-	·5 5 3.9	6
100	Online Professionalism-2018 Update of European Association of Urology (@Uroweb) Recommendations on the Appropriate Use of Social Media. <i>European Urology</i> , 2018 , 74, 644-650	10.2	38
99	Patterns of care and outcomes for men diagnosed with prostate cancer in Victoria: an update. <i>ANZ Journal of Surgery</i> , 2018 , 88, 1037-1042	1	9
98	Stereotactic Abative Body Radiotherapy (SABR) for Oligometastatic Prostate Cancer: A Prospective Clinical Trial. <i>European Urology</i> , 2018 , 74, 455-462	10.2	150
97	Low anterior resection adjacent to a pancake kidney: case report. ANZ Journal of Surgery, 2017, 87, E33.	3 ₁ E334	1

(2016-2017)

96	Predicting prostate tumour location from multiparametric MRI using Gaussian kernel support vector machines: a preliminary study. <i>Australasian Physical and Engineering Sciences in Medicine</i> , 2017 , 40, 39-49	1.9	20
95	Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectories. <i>Nature Communications</i> , 2017 , 8, 13671	17.4	128
94	Re: Diagnostic Accuracy of Multi-parametric MRI and TRUS Biopsy in Prostate Cancer (PROMIS): A Paired Validating Confirmatory Study. <i>European Urology</i> , 2017 , 72, 151	10.2	2
93	Population-based study of grade progression in patients who harboured Gleason 3I+IB. <i>World Journal of Urology</i> , 2017 , 35, 1689-1699	4	1
92	Citation indices for social media articles in urology. <i>BJU International</i> , 2017 , 119 Suppl 5, 47-52	5.6	6
91	Re: Radiation With or Without Antiandrogen Therapy in Recurrent Prostate Cancer. <i>European Urology</i> , 2017 , 72, 320	10.2	O
90	Ga-prostate-specific membrane antigen-positron emission tomography/computed tomography in advanced prostate cancer: Current state and future trends. <i>Prostate International</i> , 2017 , 5, 125-129	3.4	24
89	Systematic Review Links the Prevalence of Intraductal Carcinoma of the Prostate to Prostate Cancer Risk Categories. <i>European Urology</i> , 2017 , 72, 492-495	10.2	52
88	The Role of Local Therapy for Oligometastatic Prostate Cancer: Should We Expect a Cure?. <i>Urologic Clinics of North America</i> , 2017 , 44, 623-633	2.9	9
87	Relevance of DNA damage repair in the management of prostate cancer. <i>Current Problems in Cancer</i> , 2017 , 41, 287-301	2.3	11
86	Prostate Imaging Reporting and Data System score of four or more: active surveillance no more. <i>BJU International</i> , 2017 , 119, 9-12	5.6	4
85	An online psychological intervention can improve the sexual satisfaction of men following treatment for localized prostate cancer: outcomes of a Randomised Controlled Trial evaluating My Road Ahead. <i>Psycho-Oncology</i> , 2017 , 26, 975-981	3.9	24
84	Salvage robotic prostatectomy for radio recurrent prostate cancer: technical challenges and outcome analysis. <i>Minerva Urology and Nephrology</i> , 2017 , 69, 26-37	2.3	9
83	Planning for the post-antibiotic era - why we must avoid TRUS-guided biopsy sampling. <i>Nature Reviews Urology</i> , 2016 , 13, 559-60	5.5	8
82	International Trends in Prostate Cancer 2016 , 127-132		
81	Management of Locally Advanced (Nonmetastatic) Prostate Cancer 2016 , 467-477		
80	Australian patterns of prostate cancer care: Are they evolving?. Prostate International, 2016, 4, 20-4	3.4	6
79	Sensitivity, Specificity, and Predictors of Positive Ga-Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer: A Systematic Review and Meta-analysis. <i>European Urology</i> , 2016 , 70, 926-937	10.2	648

Prostate Cancer Registries: Current Status and Future Directions. European Urology, 2016, 69, 998-1012 10.2 39 78 The Surgical Anatomy of the Prostate **2016**, 253-263 77 Words of Wisdom. Re: Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. 76 10.2 European Urology, **2016**, 69, 540 Updates of prostate cancer staging: Prostate-specific membrane antigen. Investigative and Clinical 1.9 Urology, 2016, 57, S147-S154 A prospective study of the short-term quality-of-life outcomes of patients undergoing 5.6 7 74 transperineal prostate biopsy. BJU International, 2016, 118, 60-7 Patterns-of-care and health economic analysis of robot-assisted radical prostatectomy in the 5.6 48 73 Australian public health system. BJU International, 2016, 117, 930-9 Training in minimally invasive surgery in urology: European Association of Urology/International 5.6 72 29 Consultation of Urological Diseases consultation. BJU International, 2016, 117, 515-30 Developing and evaluating Robocare; an innovative, nurse-led robotic prostatectomy care pathway. 2.8 6 European Journal of Oncology Nursing, 2016, 21, 120-5 Activity, content, contributors, and influencers of the twitter discussion on urologic oncology. 2.8 70 35 Urologic Oncology: Seminars and Original Investigations, 2016, 34, 377-83 69 Cytoreductive surgery for men with metastatic prostate cancer. Prostate International, 2016, 4, 103-6 3.4 Integrating Social Media into Urologic Health care: What Can We Learn from Other Disciplines?. 68 2.9 13 Current Urology Reports, 2016, 17, 13 Emerging trends in prostate cancer literature: medical progress or marketing hype?. BJU 67 5.6 *International*, **2016**, 117, 14-6 66 Gleason pattern 4: active surveillance no more. BJU International, 2016, 117, 856-7 5.6 11 "We Used a Validated Questionnaire": What Does This Mean and Is It an Accurate Statement in 65 1.6 25 Urologic Research?. *Urology*, **2015**, 85, 1304-10 Reply: To PMID 25881862. Urology, 2015, 85, 1310-1 1.6 64 Targeted local therapy in oligometastatic prostate cancer: a promising potential opportunity after 63 5.6 8 failed primary treatment. BJU International, 2015, 116, 170-2 Preservation of the neurovascular bundles is associated with improved time to continence after 62 radical prostatectomy but not long-term continence rates: results of a systematic review and 10.2 96 meta-analysis. European Urology, 2015, 68, 692-704 Transperineal prostate biopsy: template-guided or freehand?. BJU International, 2015, 115, 681-3 5.6 61

(2014-2015)

60	The social media revolution is changing the conference experience: analytics and trends from eight international meetings. <i>BJU International</i> , 2015 , 115, 839-46	5.6	126
59	The current use of active surveillance in an Australian cohort of men: a pattern of care analysis from the Victorian Prostate Cancer Registry. <i>BJU International</i> , 2015 , 115 Suppl 5, 50-6	5.6	68
58	Online and social media presence of Australian and New Zealand urologists. <i>BJU International</i> , 2015 , 116, 984-9	5.6	27
57	Case Discussion: Intermediate-risk Prostate Cancer: The Case for Radical Treatment. <i>European Urology Focus</i> , 2015 , 1, 210-211	5.1	
56	Identification of candidates for observation. Current Opinion in Urology, 2015, 25, 252-7	2.8	2
55	Proton therapy websites: information anarchy creates confusion. <i>BJU International</i> , 2015 , 115, 183-5	5.6	5
54	Patient-derived xenografts reveal that intraductal carcinoma of the prostate is a prominent pathology in BRCA2 mutation carriers with prostate cancer and correlates with poor prognosis. <i>European Urology</i> , 2015 , 67, 496-503	10.2	73
53	The emerging use of Twitter by urological journals. <i>BJU International</i> , 2015 , 115, 486-90	5.6	77
52	The Melbourne Consensus Statement on the early detection of prostate cancer. <i>BJU International</i> , 2014 , 113, 186-8	5.6	50
51	Words of wisdom. Re: A new concept for early recovery after surgery in patients undergoing radical cystectomy for bladder cancer: results of a prospective randomized study. <i>European Urology</i> , 2014 , 66, 392	10.2	
50	Word of wisdom. Re: enzalutamide in metastatic prostate cancer before chemotherapy. <i>European Urology</i> , 2014 , 66, 785-6	10.2	1
49	Development, feasibility and usability of an online psychological intervention for men with prostate cancer: My Road Ahead. <i>Internet Interventions</i> , 2014 , 1, 188-195	4.4	19
48	Positive surgical margins: rate, contributing factors and impact on further treatment: findings from the Prostate Cancer Registry. <i>BJU International</i> , 2014 , 114, 680-90	5.6	33
47	Glutamate/glutamine and neuronal integrity in adults with ADHD: a proton MRS study. <i>Translational Psychiatry</i> , 2014 , 4, e373	8.6	57
46	Words of wisdom. Re: Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. <i>European Urology</i> , 2014 , 66, 1187-8	10.2	0
45	NWhat is this active surveillance thing?NMenN and partnersN eactions to treatment decision making for prostate cancer when active surveillance is the recommended treatment option. <i>Psycho-Oncology</i> , 2014 , 23, 1391-8	3.9	40
44	Engaging responsibly with social media: the BJUI guidelines. <i>BJU International</i> , 2014 , 114, 9-11	5.6	63
43	Sepsis and NuperbugsNshould we favour the transperineal over the transrectal approach for prostate biopsy?. <i>BJU International</i> , 2014 , 114, 384-8	5.6	136

42 Renal Trauma **2014**, 161-168

41	Abnormal Digital Rectal Examination 2014 , 15-21		
40	A Global Perspective from the Prostate Cancer World Congress. <i>BJU International</i> , 2013 , 112, 1-2	5.6	
39	Words of wisdom. Re: Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). <i>European Urology</i> , 2013 , 63, 1131-2	10.2	1
38	Words of wisdom. Re: Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial. <i>European Urology</i> , 2013 , 64, 1015-6	10.2	3
37	Long-term outcomes of robot-assisted radical cystectomy for bladder cancer. <i>European Urology</i> , 2013 , 64, 219-24	10.2	58
36	A preclinical xenograft model identifies castration-tolerant cancer-repopulating cells in localized prostate tumors. <i>Science Translational Medicine</i> , 2013 , 5, 187ra71	17.5	46
35	No excuse not to report complications using standardized methodology. <i>Canadian Urological Association Journal</i> , 2013 , 7, E445	1.2	
34	Patterns of care for men diagnosed with prostate cancer in Victoria from 2008 to 2011. <i>Medical Journal of Australia</i> , 2013 , 198, 540-5	4	67
33	Immediate/Early Surgical Complications 2013 , 997-1011		
32	The dilemmas of prostate cancer screening. <i>Medical Journal of Australia</i> , 2013 , 199, 583	4	
31	Focal therapy for localised prostate cancer: are we asking the correct research questions?. <i>BJU</i> International, 2012 , 109, 1-3	5.6	6
30	Analysis of early complications of robotic-assisted radical cystectomy using a standardized reporting system. <i>Urology</i> , 2011 , 77, 357-62	1.6	78
29	Re: Miocinovic et al.: Avoiding androgen deprivation therapy in men with high-risk prostate cancer: the role of radical prostatectomy as initial treatment. (Urology 2011;77:946-950). <i>Urology</i> , 2011 , 78, 724-5; author reply 725	1.6	
28	Prostate tumour volume is an independent predictor of early biochemical recurrence in a high risk radical prostatectomy subgroup. <i>Pathology</i> , 2011 , 43, 138-42	1.6	25
27	Immunohistochemical study of the cavernous nerves in the periprostatic region. <i>BJU International</i> , 2011 , 107, 1210-5	5.6	50
26	Learning Robotic-Assisted Radical Prostatectomy: How to Start and How to Get Better 2011 , 71-80		
25	Live surgical demonstrations in urology: valuable educational tool or putting patients at risk?. <i>BJU International</i> , 2010 , 106, 1571-4	5.6	22

(2008-2010)

24	Robotic-assisted laparoscopic pyeloplasty: initial Australasian experience. <i>Journal of Robotic Surgery</i> , 2010 , 3, 209-13	2.9	1
23	Downsides of robot-assisted laparoscopic radical prostatectomy: limitations and complications. <i>European Urology</i> , 2010 , 57, 735-46	10.2	90
22	Operative details and oncological and functional outcome of robotic-assisted laparoscopic radical prostatectomy: 400 cases with a minimum of 12 months follow-up. <i>European Urology</i> , 2009 , 55, 1358-66	i 10.2	140
21	Outcomes after robot-assisted laparoscopic radical prostatectomy. <i>Asian Journal of Andrology</i> , 2009 , 11, 94-9	2.8	8
20	High-intensity focused ultrasound for localized prostate cancer: initial experience with a 2-year follow-up. <i>BJU International</i> , 2009 , 104, 200-4	5.6	40
19	Is Clavien the new standard for reporting urological complications?. BJU International, 2009, 104, 434-6	5.6	49
18	The science behind haptics in robotic urological surgery. BJU International, 2009, 104, 433-4	5.6	2
17	IMMUNOHISTOCHEMICAL STUDY OF THE CAVERNOUS NERVES IN THE PERI-PROSTATIC REGION. <i>Journal of Urology</i> , 2009 , 181, 577-578	2.5	2
16	Robotic technology in surgery: current status in 2008. ANZ Journal of Surgery, 2008, 78, 1076-81	1	20
15	Robotically assisted radical cystectomy. <i>BJU International</i> , 2008 , 101, 1489-90	5.6	12
14	Robotically assisted laparoscopic pyeloplasty. <i>BJU International</i> , 2008 , 102, 136-51	5.6	7
13	Robotic-assisted laparoscopic radical cystectomy with extracorporeal urinary diversion: initial experience. <i>European Urology</i> , 2008 , 54, 570-80	10.2	139
12	State-of-the-Art in Force and Tactile Sensing for Minimally Invasive Surgery. <i>IEEE Sensors Journal</i> , 2008 , 8, 371-381	4	365
11	Hand-assisted laparoscopic nephrectomy for renal cell cancer with renal vein tumor thrombus. <i>Urology</i> , 2008 , 72, 268-72	1.6	26
10	Air-cushion force sensitive probe for soft tissue investigation during minimally invasive surgery 2008 ,		6
9	Contralateral Recurrence of Testicular Tumor: Which Patients Need Biopsy at Initial Presentation?. <i>Current Urology</i> , 2008 , 2, 51-53	1.7	
8	Robotic urology in the United Kingdom: experience and overview of robotic-assisted cystectomy. Journal of Robotic Surgery, 2008 , 1, 235-42	2.9	1
7	Salvage robotic-assisted laparoscopic radical prostatectomy following failed primary high-intensity focussed ultrasound treatment for localised prostate cancer. <i>Journal of Robotic Surgery</i> , 2008 , 2, 201-3	2.9	6

6	High prostatic fascia release or standard nerve sparing? A viewpoint from the Royal Melbourne Hospital. <i>Journal of Robotic Surgery</i> , 2008 , 2, 181-5	2.9	3
5	Robotic-Assisted Laparoscopic Pyeloplasty 2008 , 133-148		
4	High-intensity focused ultrasound for treating prostate cancer. BJU International, 2007, 99, 28-32	5.6	19
3	Nanorobots for Laparoscopic Cancer Surgery 2007 ,		10
2	The history of robotics in urology. World Journal of Urology, 2006, 24, 120-7	4	35
1	Laparoscopic reconstructive urology. <i>Journal of Minimal Access Surgery</i> , 2005 , 1, 181-7	1.2	2